Online citations, reference lists, and bibliographies.
← Back to Search

The Pattern Of Lymph Node Involvement Influences Outcome After Extrapleural Pneumonectomy For Malignant Mesothelioma.

J. Edwards, D. Stewart, A. Martin-Ucar, S. Muller, C. Richards, D. Waller
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE We sought to examine the distribution and prognostic implications of nodal metastasis in patients undergoing extrapleural pneumonectomy for malignant mesothelioma in a specialist center. METHODS We have examined the lymphadenectomy specimens from 92 consecutive cases of malignant mesothelioma undergoing extrapleural pneumonectomy from September 1999 through February 2005 inclusive. Nodal stations (Naruke) were assigned to all nodes, and patients were staged according to the current International Union Against Cancer system. The status and number of nodes in each station were recorded, and results were correlated with the results of preoperative mediastinoscopic findings (n = 30) and survival. RESULTS The nodal distribution was 48 N0, 9 N1, and 35 N2. Single and multistation nodal involvement was present in 20 and 24 cases, respectively. Among the patients undergoing mediastinoscopy, N2 disease after extrapleural pneumonectomy occurred in 10 (33%). Skip N2 metastasis was present in 10 (42%) cases. Positive N2 nodes inaccessible by mediastinoscopy were present in 17 (49%) cases. N2 metastasis was associated with reduced survival (P = .02), but there was no difference between N1 and N2 cases (P = .4). The number of positive nodes correlated with survival (P = .001), although the number of involved stations and their anatomic location did not. There was no difference in survival between skip N2 cases and either other N2 or N1 cases. CONCLUSIONS The classical anatomic location is not as important as the scatter of nodal involvement. Every effort should be made to obtain biopsy specimens from as many stations as possible before undertaking extrapleural pneumonectomy for malignant mesothelioma.
This paper references
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1016/J.EJCTS.2004.12.028
Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations.
D. Stewart (2005)
10.1378/CHEST.111.6.1710
Revisions in the International System for Staging Lung Cancer.
C. Mountain (1997)
10.1164/AJRCCM.153.1.8542156
Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study.
C. Boutin (1996)
10.1016/0169-5002(89)90425-x
Extended cervical mediastinoscopy. A single staging procedure for bronchogenic carcinoma of the left upper lobe.
R. Ginsberg (1987)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1016/S0003-4975(03)00010-9
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.
J. H. Schouwink (2003)
10.1016/S0022-5223(99)70419-8
Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer.
A. Graham (1999)
10.1016/S0003-4975(10)61856-5
The Pleura in Health and Disease
J. Chrétien (1986)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/J.EJCTS.2003.12.001
The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma.
J. Pilling (2004)
10.1016/J.ATHORACSUR.2004.06.081
Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.
M. Riquet (2005)
10.1097/00063198-199707000-00011
Diseases of the pleura.
R. Light (1995)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/S1010-7940(01)00594-2
Trimodality management of malignant pleural mesothelioma.
G. Maggi (2001)
10.1200/JCO.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.1016/S1010-7940(03)00609-2
Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma?
D. Stewart (2003)



This paper is referenced by
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
FATTORI PROGNOSTICI (2012)
10.2174/9781681081946116010023
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
Tommaso Claudio Mineo and Vincenzo Ambrogi (2016)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1016/J.PNEUMO.2011.04.002
Mésothéliome pleural : où en sont la chirurgie radicale et le traitement multimodal ?
Pierre Bonnette (2011)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1510/icvts.2009.213611
Staging algorithm for diffuse malignant pleural mesothelioma.
M. Zieliński (2010)
10.1016/J.EJCTS.2007.09.039
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
A. Nakas (2008)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
10.1093/ejcts/ezr251
The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
A. Nakas (2012)
10.1016/j.athoracsur.2008.01.088
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
10.1097/SLA.0000000000000903
Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma: Novel Prognostic Implications of Combined N1 and N2 Nodal Involvement Based on Experience in 529 Patients
D. Sugarbaker (2014)
10.1177/1753465816628800
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
10.1007/s12253-009-9170-0
Differential Expression of Ki-67 and Sex Steroid Hormone Receptors Between Genders in Peritoneal Mesothelioma
Terence C. Chua (2009)
10.1016/j.ijsu.2017.10.034
The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database.
S. Wang (2017)
10.3892/or.2013.2800
Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.
I. Hysi (2014)
10.5772/55722
Malignant Pleural Mesothelioma and the Role of Non– Operative Therapies
K. Lau (2013)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
10.1016/j.ejcts.2009.12.039
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
Apostolos Nakas (2010)
10.1002/DC.20740
Endoscopic ultrasound‐guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma
S. Bean (2008)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1016/j.ejcts.2008.06.010
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
A. Nakas (2008)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.21037/tlcr-19-488
Does size matter? -a population-based analysis of malignant pleural mesothelioma.
J. He (2020)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.3978/j.issn.2225-319X.2012.11.05
Standardizing surgical treatment in malignant pleural mesothelioma.
David C. Rice (2012)
10.1016/j.ctrv.2012.11.004
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
C. Pinto (2013)
10.4414/smw.2012.13686
Long term survival after trimodal therapy in malignant pleural mesothelioma.
R. Fahrner (2012)
10.1007/978-1-4471-6404-3_51
Surgical and Medical Therapy for Malignant Pleural Mesothelioma
Christopher Cao (2014)
10.1016/J.THORSURG.2007.07.005
From trees to wood and back: perspective on clinical data analysis in thoracic surgery.
E. Blackstone (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar